Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by t…
The INSULIN Act of 2026 requires group and individual health plans to cover certain "selected insulin products" without a deductible and caps cost-sharing per 30-day supply (generally $35 or the lesser of $35 and 25% of negotiated price). It forbids most prior authorization or similar limits for those insulin products, extends similar protections to catastrophic plans, and allows expedited review for biosimilars when competition is inadequate.
Support for out-of-pocket caps versus concern about federal plan mandates
Relative to its intended legislative type, this bill is a substantive policy change that is generally well-structured in statutory form: it amends relevant statutes explicitly, sets clear cost-sharing caps and effective dates, creates an assistance/grant program with duties and conflict-of-interest standards, requires a GAO study, and adds a defined process to expedite certain biosimilar reviews.
The INSULIN Act of 2026 requires group and individual health plans to cover certain "selected insulin products" without a deductible and caps cost-sharing per 30-day supply (generally $35 or the lesser of $35 and 25% of negotiated price).
It forbids most prior authorization or similar limits for those insulin products, extends similar protections to catastrophic plans, and allows expedited review for biosimilars when competition is inadequate.
The bill creates a federally funded resource center and 24/7 hotline to help uninsured people access insulin assistance, mandates a GAO study on uninsured insulin users, and authorizes modest grants for FY2027–2032.
Substantive, popular patient protections increase prospects, but entrenched pharma/PBM and insurer opposition plus Senate procedural barriers and missing cost offsets reduce odds.
Relative to its intended legislative type, this bill is a substantive policy change that is generally well-structured in statutory form: it amends relevant statutes explicitly, sets clear cost-sharing caps and effective dates, creates an assistance/grant program with duties and conflict-of-interest standards, requires a GAO study, and adds a defined process to expedite certain biosimilar reviews. It also provides administrative authority to agencies for implementation.
Support for out-of-pocket caps versus concern about federal plan mandates
These are examples from the analysis, not a ranked list of the most-affected groups.
Support for out-of-pocket caps versus concern about federal plan mandates
Generally supportive.
The bill directly limits out-of-pocket insulin costs, removes barriers like prior authorization, and funds outreach to uninsured people.
It also promotes biosimilar competition, which aligns with goals to lower drug prices long-term.
Cautiously favorable but pragmatic.
The bill reduces point-of-care costs and streamlines access, which are clear consumer benefits, but raises legitimate questions about insurer responses, premium impacts, and administrative implementation.
Will want monitoring, implementation detail, and cost offsets.
Skeptical.
The bill imposes federal mandates on private plans, limits plan design, and risks raising insurance costs through regulatory micromanagement.
The waiver of administrative procedures and new grant spending are also concerning.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Substantive, popular patient protections increase prospects, but entrenched pharma/PBM and insurer opposition plus Senate procedural barriers and missing cost offsets reduce odds.
The bill has not accumulated any surfaced votes yet.
Support for out-of-pocket caps versus concern about federal plan mandates
Substantive, popular patient protections increase prospects, but entrenched pharma/PBM and insurer opposition plus Senate procedural barrie…
Relative to its intended legislative type, this bill is a substantive policy change that is generally well-structured in statutory form: it amends relevant statutes explicitly, sets clear cost-sharing caps and effective…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.